common errors in insulin therapy
TRANSCRIPT
Common Errors in Insulin Therapy
Anil Bhansali Department of Endocrinology PGIMER, Chandigarh
Insulin Therapy1. Alternative therapy to insulin in
T1DM2. Delay in initiating insulin therapy3. Pre-injection assessment4. Insulin injection techniques5. Regimens of insulin treatment6. Insulin analogues7. Consequences of Insulin Therapy
-Short term -Long term
Alternative therapy to insulin in T1DM!
Omission of insulin in T1DM is SUICIDAL
Never stop insulin even during sickness
Follow sick day guidelines
Delay in Initiation of Insulin Therapy
The 2 Defects of T2DM
Insulin resistanceInsulin deficiency
Insulin resistance alone cannot produce T2DM
AJM 2000
Adapted from Holman RR. Diabetes Res Clin Pract 1998;40(Suppl.):S21–S25
Adapted from Mudaliar S et al. In: Ellenberg and Rifkin’s Diabetes Mellitus, 6th ed. New York, NY:Appleton and Lange; 2003:531-557.
Add insulin
Oral agent 2 Oral agents
Inadequate non-pharmacologic therapy
3 Oral agents3 Oral agents
Previous Algorithm – Type 2
4 Oral* agents4 Oral* agents
*-Indian scenario
At insulin initiation, the average patient had: 5 years with A1C >8% 10 years with A1C >7%
Standard Approaches to Therapy Result inProlonged Exposure to Elevated Glucose
Brown JB, et al. Diabetes Care. 2004;27:1535-1540.
Sulfonylurea or Metformin Monotherap
y
ADA Goal <7%
CombinationTherapy
Diet/Exercise
Mean
A1
C a
t Last
Vis
it
YearsDiagnosis 2 3 4 5 6 7 8 9 10
9.6%
9.0%8.6%
6%
7%
8%
9%
10%
Insulin
Psychological Insulin Resistance(PIR)
ADA 2012 Algorithm for T2DM
DPP-4=dipeptidyl peptidase-4; T2DM=type 2 diabetes mellitus; TZD=thiazolidinedioneAACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007; 13 (Suppl 1): 16–34.
American Association of Clinical Endocrinologists: algorithm for patients with T2DM
Drug-naïve patientsHbA1c 6%–7%
Initiate monotherapyMetformin, TZD, secretagogues, DPP-4 inhibitors, α-glucosidase inhibitors
HbA1c 7%–8% Initiate combination therapySecretagogue + metformin, TZD, or α-glucosidase inhibitor TZD + metforminDPP-4 + metformin or TZDSecretagogue + metformin + TZD Fixed-dose combinationsInsulin
As aboveExenatide may be combined with oral therapies in patients not achieving goals
Patients currently pharmacologically treated
HbA1c 8%–10% Intensify combination therapyTo address fasting and postprandial glucose levels
HbA1c >10% Initiate / intensify insulin therapy
Lif
esty
le C
han
ges
When to Add insulin?
At the initial diagnosis Failure of maximal doses of monotherapyFailure of submaximal doses of 2 OHA’s Failure of maximal doses of 2 OHA’s Failure of submaximal doses of triple
therapy
At the Diagnosis of T2DMSeverely symptomaticFPG>250 mg/dlRPG >300mg/dlHbA1c >10%Presence of ketosisBMI < 23 Kg/m2
Cardiac / renal / hepatic dysfunctions
Critically ill patients
ORIGIN study
N Engl J Med 2012; 367:309-318
Add Insulin
Patient on two OHA’s FPG > 130 mg/dlPPG > 180 mg/dlHbA1c >8.5%Tighter control is desiredContraindication/intolerant to
other OHA’s
Pre-injection Assessment is Not Done!
Pre- injection Assessment
Injection-related concernsPsychological insulin resistance (personal failure, anticipated
pain, once on insulin always on insulin)
Pre-injection Assessment
-Dexterity problems -Cognitive capacity -Health literacy -Numeracy skills -Visual impairment -Local infections, ulcers and
scars
How insulin should be stored ?
Injection StorageStore insulin in use at room
temperature (15-25oC) and discard 30 days after initial use
Short acting analogue,Lispro, in use should be stored at 40 C after use
Currently unused vials/refill cartridges should be refrigerated
Never freeze the insulin
Injection Technique is not Properly Advised!
Injection TechniqueRe-suspension of cloudy insulin is
essential (Rolled 20 cycles)Needle length 4-6 mmSite of injection should be looked
for lipohypertrophy or any bruise/blisters
Recommend use of alcohol swabs or cotton ball dipped in water for cleaning
Injection site : Abdomen < thigh <arm
Ensure the correct insulin syringe with correct strength of insulin (40U vial with 40U syringe)
Insulin pen should be primed with two units of insulin as the first step
Insert the needle at 90o to the skin fold and count till 10 before pulling the needle out
Needle site should not be massagedInjection site should be rotated
Insulin Dose Prescription is not Properly Written!
Inadvertent use of abbreviationsInj Reg insulin 4URoute of administration is not
mentionedSite of administration is not
writtenTime of administration is missingPremixed insulin strengths are
not mentioned (25:75, 30:70, 50:50)
Insulin is administered through clothing !
Pre- and post-injection site assessment is not possible
The needle becomes unsterile and can cause infection
Skin pinch-up may not be correct through clothing
Fiber from the cloth could enter the skin and cause irritation
Insulin is Administered just Prior to Meal!
Lag time between insulin administration and meal
-30-45 min for conventional insulin (Hexamer to monomer)
-5-10 min for short acting analoguesTime of administration of long acting
analogues -Preferably at bed time, usually at fixed
time -If early morning hypoglycemia, then
administer in morning
Short acting insulin is used twice or thrice a day without intermediate or long acting
insulin!
This strategy will never control fasting hyperglycemia as short acting insulin acts
only for 4-6 hrs.
Characteristics of Currently Available Insulin
Insulin Onset of action(h)
Peak action(h)
Duration(h)
NPH 1-3 4-10 10-20
Glargine 2-4 No peak 20-24
Detemir 2 No peak 16-24
Regular 0.5-1 2-3 5-8
Lispro/aspart 0.1-0.25 0.5-1.5 3-5
Lispro 25/75 0.25-0.5 5.8 12-24
Aspart 30/70 0.17-0.33 2.4 ± 0.8 12-24
Insulin Regimens
Basal-bolus (3 prandial and one/two NPH or Glargine)Only Basal (NPH or Glargine or Detemir)Premixed twice a day (30:70 either conventional or analogues)Premixed twice a day + one regular insulin at
LunchOne regular or short acting analogues to
control post-prandial hyperglycemiaOne dose of premixed insulin before major
meals
Insulin Regimens Fasting hyperglycemia -NPH -Glargine at bed time -Detemir Post-prandial hyperglycemia -Regular insulin -Short acting analogues -Premixed Predinner hyperglycemia -NPH, Glargine, Detemir at morning -Premixed before lunch, if it is a major meal ‘Global hyperglycemia’
-Basal and bolus
What should be targeted?
-FPG, PPG, HbA1c or all three-Which should be the first?
Post-prandial hyperglycaemia
Post-prandial hyperglycaemia contributes HbA1c ~1%
B=breakfast; L=lunch; D=dinner.Adapted from Riddle MC. Diabetes Care. 1990;13:676-686.
Pla
sm
a g
lucose (
mg
/dL) 300
200
100
0
Time of day (h)6 12 18 24 6
Uncontrolled Diabetes HbA1c 8%
Fasting hyperglycaemia
Basal hyperglycaemia contributes ~2%
B
L
D
NormalHbA1c ~5%
Basal vs Post-Prandial Hyperglycemia – A1c
HbA1c: LimitationsDoes not detect glycemic
excursionsDoes not reveal hypoglycemiaCautions:
◦Anemia◦Uremia◦EPO therapy
Short acting and Long acting Analogues are Indiscriminately
Used!
Short acting analogues used as i.v infusion for the treatment of hyperglycemic emergencies
Use of short acting analogues with premixed conventional insulin
Mixing of glargine with short acting insulin
Premixed insulin twice a day and glargine at bedtime
Distinctive Uses of Analogues
Short acting analogues -School going children -Pregnancy with diabetes -Busy executives -GastroparesisLong acting analogues -Elderly subjects -Targeting HbA1c <6.5% -Inability to inject multiple injections
Somogyi phenomenon is not Recognized?
Somogyi PhenomenonPost-hypoglycaemic
hyperglycemiaWide swings in blood glucose
profileCommon cause of fasting
hyperglycemiaPerform 4am BG level (<80mg/dl)
Dawn Phenomenon is usually Missed!
Dawn PhenomenonEarly morning hyperglycemia (nocturnal GH surge, increased
insulin clearance)Perform BG at 4 am >80mg/dl
Use of Biosimilars!
These preparations are structurally similar but pharmacokinetics and therapeutic efficacy are variable
Biosimilars with suboptimal efficacy may induce DKA
Consequences of Insulin Therapy
ImmediateHypoglycemiaShort term -Weight gain -Worsening of retinopathy and neuropathyLong term -Malignancy
Insulin-Induced Hypoglycemia
Major barrierCommon with -Advanced duration of disease -Concurrent OHA’s -Older age, DKD
ConclusionsDiabetes is an insulin deficient
disorder, hence it should be repleted
Insulin administration is a state-of-art
The time of initiation may be variable but delay should be avoided
Close monitoring should be done for hypoglycemia and weight gain
Thank you